Literature DB >> 11314004

Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells.

Y Fukuchi1, M Kizaki, K Yamato, C Kawamura, A Umezawa, T Nishihara, Y Ikeda.   

Abstract

Activin A, one member of the transforming growth factor (TGF)-beta superfamily, is known to be a commitment factor for cell death and differentiation. In the present study, we demonstrate that human chronic myeloid leukemia (CML) cell lines, KU812 and K562 cells, either induced apoptosis or differentiation, respectively, by treatment with activin A. During these cell fate decisive events caused by activin A, rapid and transient up-regulation of Mcl-1 was observed in both cell lines. In activin A-induced apoptosis of KU812 cells, continuous up-regulation of Bax was observed. After the decrease in Mcl-1 expression had occurred, activation of caspase-9 and caspase-3 and cleavage of DFF45 were shown to take place in KU812 cells, resulting in the fragmentation of the genomic DNA of the cells. In contrast, the down-regulation of Mcl-1 without up-regulation of Bax caused accumulation of hemoglobin (Hb) contents in activin A-treated K562 cells. Interestingly, erythropoietin (EPO) prevented activin A-induced apoptosis with continuous expression of Mcl-1 and caused KU812 cells to undergo erythroid differentiation. To address the role of Mcl-1 in activin A-treated CML cells, KU812 and K562 cells were stably transfected with cDNA encoding Mcl-1 (designated as KU812/mcl and K562/mcl cells). As in combined effect of activin A and EPO on the parental KU812 cells, activin A induced differentiation, but not apoptosis, of KU812/mcl cells without modulating Bax levels. Activin A-treated K562/mcl cells, as well as parental cells, were only differentiated to erythroid cells. These results suggest that Mcl-1 is an early inducible gene activated by the activin A signaling pathway for both cellular differentiation and apoptosis, and continuous expression of Mcl-1 may be contributed to differentiation signals to the erythroid lineage in CML cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314004     DOI: 10.1038/sj.onc.1204142

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.

Authors:  Barbara H Jung; Stayce E Beck; Jennifer Cabral; Eddy Chau; Betty L Cabrera; Antonio Fiorino; E Julieta Smith; Melanie Bocanegra; John M Carethers
Journal:  Gastroenterology       Date:  2006-11-16       Impact factor: 22.682

Review 2.  BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.

Authors:  Danilo Perrotti; Jason G Harb
Journal:  Leuk Lymphoma       Date:  2011-01-11

3.  Cryptosphaerolide, a cytotoxic Mcl-1 inhibitor from a marine-derived ascomycete related to the genus Cryptosphaeria.

Authors:  Hyuncheol Oh; Paul R Jensen; Brian T Murphy; Catherine Fiorilla; John F Sullivan; Timothy Ramsey; William Fenical
Journal:  J Nat Prod       Date:  2010-05-28       Impact factor: 4.050

4.  TGF-β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis.

Authors:  Yuyi Wang; Chi Du; Nan Zhang; Mei Li; Yanyang Liu; Maoyuan Zhao; Feng Wang; Feng Luo
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

5.  Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats.

Authors:  Chanil Moon; Melissa Krawczyk; Dongchoon Ahn; Ismayil Ahmet; Doojin Paik; Edward G Lakatta; Mark I Talan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

6.  p73 plays a role in erythroid differentiation through GATA1 induction.

Authors:  Fernando Marqués-García; Nuria Ferrandiz; Rosalía Fernández-Alonso; Laura González-Cano; Marta Herreros-Villanueva; Manuel Rosa-Garrido; Belén Fernández-García; José P Vaque; Margarita M Marqués; María Eugenia Alonso; José Carlos Segovia; Javier León; María C Marín
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

Review 7.  Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.

Authors:  Pankit Vachhani; Prithviraj Bose; Mohamed Rahmani; Steven Grant
Journal:  Physiol Genomics       Date:  2014-05-13       Impact factor: 3.107

8.  The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.

Authors:  F Pellicano; P Simara; A Sinclair; G V Helgason; M Copland; S Grant; T L Holyoake
Journal:  Leukemia       Date:  2011-04-12       Impact factor: 11.528

9.  Role of STAT3 in Transformation and Drug Resistance in CML.

Authors:  Rajesh R Nair; Joel H Tolentino; Lori A Hazlehurst
Journal:  Front Oncol       Date:  2012-04-10       Impact factor: 6.244

10.  Use of the relative release index for histamine in LAD2 cells to evaluate the potential anaphylactoid effects of drugs.

Authors:  Shengli Han; Yanni Lv; Liyun Kong; Delu Che; Rui Liu; Jia Fu; Jiao Cao; Jue Wang; Cheng Wang; Huaizhen He; Tao Zhang; Xinzhong Dong; Langchong He
Journal:  Sci Rep       Date:  2017-10-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.